AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03587233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity level assessment
Description: The physical activity level will be assessed through the intervention titled with the Turkish version of the 'International Physical Activity Questionnaire-Short Form'. It consists of seven questions searching for the amount of walking and low, moderate and high intensity physical activities as total time in minutes per day and frequency in days per week. Sitting, as a sedentary behavior, will be evaluated separately. The scores will be achieved by the multiplication of the minutes, days and metabolic equivalent time values in a week, and over the last 7 days. Walking score and total weekly walking duration will be calculated as medium and vigorous; the physical activity level will be classified as low, moderate and high level activity.
Study NCT02204501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir 528 mg QD
Description: Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
Study NCT02688218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
Study NCT02688218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
Study NCT03676491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: Music intervention
Study NCT03413592 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement
Study NCT03413592 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Car-following test
Description: Driving with simulator program for DCV measurement
Study NCT00531453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, dexamethasone, and thalidomide
Description: VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21)~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).
Study NCT00531453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, dexamethasone, thalidomide, and cyclophosphamide
Description: VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).~Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles.
Study NCT00942760 — intervention group
Intervention type: DEVICE
Intervention: 3T MRI
Description: The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
Study NCT00848939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
Study NCT00848939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
Study NCT03413592 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement
Study NCT03498677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: presentation order
Description: section presentation one
Study NCT03498677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: alternative presentation order
Description: section presentation two
Study NCT03312738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was formulated as tablets of 5 mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) was administered in a blinded manner by continuous oral daily dosing.
Study NCT03312738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.
Study NCT03312738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.
Study NCT03312738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus Placebo
Description: Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) was administered in a blinded manner by continuous oral daily dosing.
Study NCT00546403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Adjunctive treatment with titrated dose of modafinil
Study NCT00546403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adjunctive treatment with placebo
Study NCT01394978 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard surgical techniques including staples and sutures.
Study NCT02940301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02940301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02940301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02691715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial saline plus curettage
Study NCT01394978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProGEL Pleural Air Leak Sealant with standard surgical closure
Description: ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
Study NCT01394978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProGEL Pleural Air Leak Sealant without standard surgical closure
Description: ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
Study NCT02691715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial curettage
Study NCT00183430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
Study NCT00183430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are taken orally twice per day at 10 am and bedtime.
Study NCT00183430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: All participants will undergo psychotherapy during medication treatment period.
Study NCT00183430 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy
Description: All participants will undergo psychotherapy during medication treatment period.
Study NCT06002893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholesfytol NG®) supplement
Description: General Practitioner (GP) prescribed oral Cholesfytol NG®) supplement
Study NCT00658788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate spray 0.05%
Description: clobetasol propionate spray, 0.05%, applied topically twice daily
Study NCT02543840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs plus External Facilitation
Description: Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
Study NCT02543840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Materials
Description: Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
Study NCT03774108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 850 MG
Description: 8 weeks tratment with oral metformin
Study NCT03774108 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks tratment with oral placebo
Study NCT01116557 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radiofrequency Ablation procedure
Description: Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
Study NCT01116557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation procedure
Description: Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
Study NCT03028246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 4000 System
Description: Focused ultrasound
Study NCT00658788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcitriol ointment
Description: calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
Study NCT01891201 — intervention group
Intervention type: DRUG
Intervention: Oxytocin
Description: Comparison of Primitive Newborn Reflexes between those exposed or not to Oxytocin
Study NCT02661919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emfit mattress sensor
Description: Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
Study NCT02793388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supervised primaquine treatment
Description: Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.
Study NCT02793388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised primaquine treatment
Description: Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
Study NCT05476302 — intervention group
Intervention type: OTHER
Intervention: Cognitive digital treatment
Description: The remote cognitive-rehabilitation treatment was based on Parkinson's adapted cognitive stimulation therapy (CST). Fourteen twice-weekly sessions were planned, followed by one session per week for a duration of six months for maintenance therapy. The treatment took place in groups of 4 patients in remote mode through the Microsoft-Teams platform. All subjects maintained the prescribed drug therapy and regular physiotherapy activity during the intervention.
Study NCT02577822 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Taperloc standard length stem
Study NCT02577822 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Taperloc short length stem
Study NCT02627092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper linen exposure
Description: Subjects will use hospital linens (top sheet, bottom sheet, pillow case, gown) made with copper to see if this helps reduce infections during their hospital stay.
Study NCT00000167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Laser Treatment
Description: Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
Study NCT01410968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells
Description: Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
Study NCT01687907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Study NCT03796702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deileostomy
Description: Deileostomy
Study NCT02432196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harpoon Medical Device
Description: It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
Study NCT01244477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CPT-C
Description: Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
Study NCT01863771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
Study NCT01863771 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
Study NCT03367429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: THE PROTOCOL DESCRIPTION ATTEMPTED TO OUTLINE A CONTINGINECY PLAN- MOVING TO ONE OF TWO METHODOLOGOIES DPENDING ON PRELIMINARY FINDINGS. UNFORTUNATLEY, OVER 2 YEARS RECRUITMENT WAS GROSSLY INADEQUATE PREVENTING ANY TYPE OF EVEN CURSURY PRELIMINARY DATA ANALYSIS AND FORCING THE EARLY TERMINATION OF THIS STUDY. MICHAEL W. O'DELL, MD
Study NCT00247234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schema Therapy
Description: group based schema therapy
Study NCT03438877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive dosage of PD
Description: Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 3.5. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 24-36L/day of dialysate, 1.5-2L/exchange, and 16 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
Study NCT03438877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular dosage of PD
Description: Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 2.1. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 9-12L/day of dialysate, 1.5-2L/exchange, and 6 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
Study NCT00247234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard psychiatric out-patient care
Study NCT01112319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elf care
Description: elfcare device
Study NCT03248492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
Study NCT01112319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: regular physiotherapy treatment
Study NCT03248492 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DS-8201a
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
Study NCT03023501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study NCT03023501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Study NCT02424825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Course
Description: This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
Study NCT00935818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: varenicline - 1 mg bid for 12 weeks
Study NCT00935818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: varenicline - 1 mg bid for 12 weeks
Study NCT00935818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 12 weeks
Study NCT00935818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion SR
Description: bupropion sr - 150 mg bid for 12 weeks
Study NCT01831479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days
Study NCT01831479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: Single administration of olmesartan 40mg tablet QD for 7 consecutive days
Study NCT01831479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and olmesartan
Description: Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
Study NCT03799835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
Study NCT03799835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG
Description: Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
Study NCT03799835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV perfusion
Study NCT00684619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: 1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5
Study NCT01055301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT01055301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT01055301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT01055301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT01055301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT01055301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT01055301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Study NCT01055301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT01055301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT01055301 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis